Navigation Links
NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
Date:2/4/2009

DA or European regulatory approval; any regulatory approvals which are received may offer more limited indications than anticipated; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Stephanie Carrington / Sara Ephraim (investors)
    (646) 536-7017 / 7002
    scarrington@theruthgroup.com
    sephraim@theruthgroup.com

    Jason Rando (media)
    (646) 536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Each year in the US, more ... In the military, burn injury is a ubiquitous ... care. More than 800 service members sustained burn ... slowly, remain inflamed and often become infected, producing ... functionally damaging. While developments in supportive care have ...
(Date:9/29/2014)... Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, Canadian ... three Promissory Note holders, two of whom are the ... July 2014 for a total of $ 300,000 opted ... 3,500,001 restricted common shares. Notes were repayable within one ... the coupon were convertible into common shares to be ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... METTLER TOLEDO’s new line of XPE ... precision balances as well as automated dosing ... can carry out their daily weighing tasks worry free, ... deliver consistently reliable and compliant results, thanks to new ... of the biggest challenges in analytical and micro-analytical weighing ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 2
... This release is available in German . ... in electronics. Dr. Willi Auwaerter and Professor Johannes Barth, together ... (TUM), have now presented a novel molecular switch in the ... the switch is the position of a single proton in ...
... COLUMBUS, Ohio, Dec. 12, 2011   Chemical Abstracts ... Chemical Society and the world,s authority for chemical ... InfoChem, GmbH (InfoChem), a  leader ... as datamining in chemical science documents, headquartered in ...
... Zyngenia , Inc ... antibody-based drugs called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as ... our start in September 2009, Zyngenia has made tremendous progress in ...
Cached Biology Technology:The smallest conceivable switch 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 3Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3
(Date:9/29/2014)... the age of dinosaurs, gigantic reptilesdistant relatives of modern ... in water and it was thought they didn,t much ... Tennessee, Knoxville, researcher in the thigh of one of ... Stephanie Drumheller, an earth and planetary sciences lecturer, and ... examined 220-million-year-old bite marks in the thigh bones of ...
(Date:9/29/2014)... considered capable of doing anything on their own. But ... water. In the future, such moving droplets may deliver ... to be self-moving is a feature normally ... be self-moving, report researchers from University of Southern Denmark ... , The researchers have made alcohol droplets move in ...
(Date:9/29/2014)... researchers at the University of Cambridge has shown that ... most of Greenland is more sensitive to climate change ... rising sea levels that threaten coastal communities worldwide. , ... levels of meltwater created and spilled into the ocean ... new model also takes into account the role that ...
Breaking Biology News(10 mins):Tooth serves as evidence of 220 million-year-old attack 2Scientists make droplets move on their own 2Greenland Ice Sheet more vulnerable to climate change than previously thought 2Greenland Ice Sheet more vulnerable to climate change than previously thought 3
... a telescope promise to make it easier for people ... requiring sharper distance vision. Schepens Eye Research Institute scientists ... devices in an article published in the May/June issue ... in print form to subscribers this month. ...
... A new study by researchers from Columbia University,s ... most challenging issues in infant health and preventing mother-to-child ... HIV-infected mothers had been advised that for the best ... by a rapid weaning four to six months after ...
... Pennsylvania State University College of Medicine, Hershey, Pennsylvania have ... immune response modifier with potent antiviral and antitumor activity, ... (OGFr) axis for its action. This discovery, reported ... and Medicine , provides new insights into a widely ...
Cached Biology News:Telescope embedded in glasses lens promises to make driving easier for visually impaired 2Telescope embedded in glasses lens promises to make driving easier for visually impaired 3Early cessation of breastfeeding by HIV+ women in poor countries and child survival 2Early cessation of breastfeeding by HIV+ women in poor countries and child survival 3Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
pH-insensitive fluorescence (pH 2-12)...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: